We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Could Predict Death Risk in World’s Most Common Inherited Heart Disease

By LabMedica International staff writers
Posted on 06 Jan 2026

Hypertrophic cardiomyopathy (HCM) is the world’s most common inherited heart condition and affects millions of people globally. More...

While some patients live with few or no symptoms, others develop heart failure, dangerous rhythm disturbances, or sudden cardiac arrest. Clinicians currently lack reliable tools to predict which genetically affected patients are most at risk of these life-threatening outcomes. Now, a blood test could predict who is most at risk from this common inherited heart condition

A team of scientists from Harvard Medical School (Boston, MA, USA) and University of Oxford (Oxford, UK) is developing a blood test that could forecast risk for people living with HCM. In a landmark study, the team investigated whether a blood-based biomarker could help predict disease severity in individuals with HCM. Their work focused on N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), a protein released by the heart during normal pumping.

The researchers measured NT-pro-BNP levels in blood samples from 700 patients diagnosed with HCM. These measurements were compared with detailed assessments of heart structure, blood flow, and tissue scarring. The investigators then analyzed how biomarker levels correlated with known indicators of disease progression and clinical risk.

Patients with the highest NT-pro-BNP levels showed poorer blood flow, increased scar tissue, and structural changes linked to atrial fibrillation and heart failure. Elevated levels indicated that the heart muscle was under greater strain and working harder to pump blood. The findings suggest NT-pro-BNP can serve as a predictor of future complications in HCM.

A simple blood test measuring NT-pro-BNP could transform care by allowing doctors to identify high-risk patients earlier. Those at greatest risk could be monitored more closely or receive potentially life-saving treatments, while lower-risk patients could avoid unnecessary interventions. The researchers believe that continued studies of blood biomarkers could further improve personalized risk assessment and treatment planning for patients with HCM.

Related Links:
Harvard Medical School
University of Oxford


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.